Neuspera neuromodulation device hits “gold standard” in incontinence trial

Neuspera Medical’s percutaneous sacral neuromodulation (pSNM) has hit the “gold standard”, with 84.2% of patients suffering incontinence benefitting from a 50% reduction in urgent leaks and a more than three-fold improvement in quality of life.